FDA Eyes Overhaul Of Risk Disclosure In Pharma Ads

Law360, New York (February 18, 2014, 4:02 PM EST) -- The U.S. Food and Drug Administration announced Friday that it may overhaul regulations surrounding television and radio commercials for pharmaceuticals, saying it’s concerned that advertisements describe too many risks and cause consumers to either tune out or avoid beneficial medicines.

In a public notice, the FDA took aim at the laundry list of major side effects that manufacturers are typically expected to disclose as part of ads, with the so-called major statement often consuming a large chunk of the promotional spot.

The thinking is that consumers...
To view the full article, register now.